Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus

Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin αvβ6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kate M., Desai, Ami, Delgado, Bea de Luxán, Trabulo, Sara Maria David, Reader, Claire, Brown, Nicholas F., Murray, Elizabeth R., Brentnall, Adam, Howard, Philip, Masterson, Luke, Zammarchi, Francesca, Hartley, John A., van Berkel, Patrick H., Marshall, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053198/
https://www.ncbi.nlm.nih.gov/pubmed/32194845
http://dx.doi.org/10.7150/thno.38702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053198/
https://www.ncbi.nlm.nih.gov/pubmed/32194845
http://dx.doi.org/10.7150/thno.38702

Ejemplares similares